Compare · AURA vs MRNA
AURA vs MRNA
Side-by-side comparison of Aura Biosciences Inc. (AURA) and Moderna Inc. (MRNA): market cap, price performance, sector, and recent activity on the wire.
Summary
- Both AURA and MRNA operate in Biotechnology: Biological Products (No Diagnostic Substances) (Health Care), so they compete in similar markets.
- MRNA is the larger of the two at $24.53B, about 33.9x AURA ($723.0M).
- Over the past year, AURA is up 3.9% and MRNA is up 97.7% - MRNA leads by 93.8 points.
- MRNA has been more active in the news (11 items in the past 4 weeks vs 6 for AURA).
- MRNA has more recent analyst coverage (25 ratings vs 11 for AURA).
- Company
- Aura Biosciences Inc.
- Moderna Inc.
- Price
- $6.98+1.45%
- $61.80-2.14%
- Market cap
- $723.0M
- $24.53B
- 1M return
- +11.24%
- +11.57%
- 1Y return
- +3.87%
- +97.70%
- Industry
- Biotechnology: Biological Products (No Diagnostic Substances)
- Biotechnology: Biological Products (No Diagnostic Substances)
- Exchange
- NASDAQ
- NASDAQ
- IPO
- 2021
- 2018
- News (4w)
- 6
- 11
- Recent ratings
- 11
- 25
Aura Biosciences Inc.
Aura Biosciences, Inc. operates as a biotechnology company that develops therapies to treat cancer. The company develops virus-like drug conjugates (VDC) technology platform to treat tumors of high unmet need in ocular and urologic oncology. Its AU-011, a VDC candidate, is being developed for the first line treatment of primary choroidal melanoma, a rare disease with no drugs approved. The company also develops AU-011 in additional ocular oncology indications, including choroidal metastases. Aura Biosciences, Inc. was incorporated in 2009 and is headquartered in Cambridge, Massachusetts.
Moderna Inc.
Moderna, Inc., a biotechnology company, develops therapeutics and vaccines based on messenger RNA for the treatment of infectious diseases, immuno-oncology, rare diseases, cardiovascular diseases, and auto-immune diseases. As of March 9, 2021, the company had 13 programs in clinical trials and a total of 24 development programs in six modalities comprising prophylactic vaccines, cancer vaccines, intratumoral immuno-oncology, localized regenerative therapeutics, systemic secreted and cell surface therapeutics, and systemic intracellular therapeutics. The company has strategic alliances with AstraZeneca PLC, Merck & Co., Inc., Vertex Pharmaceuticals Incorporated, Vertex Pharmaceuticals (Europe) Limited, the Biomedical Advanced Research and Development Authority, the Defense Advanced Research Projects Agency, the National Institute of Allergy and Infectious Diseases, the National Institutes of Health, the Coalition for Epidemic Preparedness Innovations, and Bill & Melinda Gates Foundation. Moderna, Inc. also has collaborations with Lonza Ltd. for the manufacture of COVID-19 vaccine; and Catalent Inc., Laboratorios Farmacéuticos Rovi, S.A., Recipharm, and Lonza Group for fill-finish manufacturing of its COVID-19 vaccine candidate, as well as Aldevron, LLC for supporting COVID-19 vaccine and additional programs in company's clinical development pipeline. The company was formerly known as Moderna Therapeutics, Inc. and changed its name to Moderna, Inc. in August 2018. Moderna, Inc. was founded in 2010 and is headquartered in Cambridge, Massachusetts.
Latest AURA
- Director Bender Jeremy was granted 30,000 shares (SEC Form 4)
- SEC Form 3 filed by new insider Bender Jeremy
- Aura Biosciences Inc. filed SEC Form 8-K: Leadership Update, Financial Statements and Exhibits
- Aura Biosciences Announces Appointment of Jeremy Bender, Ph.D., M.B.A., to Board of Directors
- Officer Kilroy Conor was granted 14,858 shares, increasing direct ownership by 7% to 232,693 units (SEC Form 4)
- SEC Form DEF 14A filed by Aura Biosciences Inc.
- SEC Form PRE 14A filed by Aura Biosciences Inc.
- Officer Gibney Anthony S sold $82,330 worth of shares (12,824 units at $6.42), decreasing direct ownership by 5% to 265,354 units (SEC Form 4) to cover withholding tax
- Director Srivastava Sapna was granted 15,000 shares, increasing direct ownership by 64% to 38,500 units (SEC Form 4)
- Director Bitetti Teresa Marie was granted 15,000 shares, increasing direct ownership by 71% to 36,000 units (SEC Form 4)
Latest MRNA
- President Hoge Stephen exercised 53,336 shares at a strike of $19.15 and sold $3,605,514 worth of shares (53,336 units at $67.60) as part of a pre-agreed trading plan (SEC Form 4)
- Moderna Announces First Participant Dosed in Phase 1 Clinical Trial Evaluating Investigational Tumor-Targeted Cancer Antigen Therapy in Solid Tumors
- SEC Form 4 filed by Director Mcdonnell Michael R.
- SEC Form 3 filed by new insider Mcdonnell Michael R.
- Moderna to Report Second Quarter 2026 Financial Results on Friday, July 31, 2026
- Moderna Inc. filed SEC Form 8-K: Leadership Update, Regulation FD Disclosure, Financial Statements and Exhibits
- Moderna Appoints Michael McDonnell to Board of Directors
- SEC Form 4 filed by Chief Commercial Officer Banque Soria Ester
- Chief Financial Officer Mock James M converted options into 1,452 shares and covered exercise/tax liability with 703 shares, increasing direct ownership by 1% to 66,436 units (SEC Form 4) to satisfy withholding tax
- SEC Form 3 filed by new insider Banque Soria Ester